Keith Lamy, MD
Family Medicine · Austin, TXNPI 1164430278
Payments from drug & device makers
Across 224 payments — averaging $19.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$590
- Novo Nordisk$510
- Gilead$491
- Sanofi-aventis U.S. LLC$408
- Boehringer Ingelheim$374
- Bayer$289
- plus $2K from 25 others
What the payments were for
- Speaking & faculty fees$4059%
- Food & beverage$4,02090%
- Education$251%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 34 | $590 |
| Novo Nordisk | 27 | $510 |
| Gilead | 27 | $491 |
| Sanofi-aventis U.S. LLC | 14 | $408 |
| Boehringer Ingelheim | 21 | $374 |
| Bayer | 16 | $289 |
| Amgen(2 entities) | 16 | $268 |
| GSK | 11 | $187 |
| Lilly USA, LLC | 10 | $185 |
| AbbVie(2 entities) | 8 | $164 |
| Sanofi | 2 | $150 |
| Astellas Pharma US Inc | 7 | $118 |
| Optos, Inc. | 1 | $116 |
| Johnson & Johnson | 5 | $93 |
| Abbott | 4 | $85 |
| Exact Sciences | 2 | $53 |
| Abiomed | 1 | $49 |
| Pfizer | 2 | $36 |
| Daiichi Sankyo Inc. | 2 | $33 |
| Amarin Pharma, Inc. | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $25 |
| Dexcom, Inc. | 1 | $25 |
| Nestle Healthcare Nutrition Inc. | 1 | $24 |
| Harmony Biosciences LLC | 1 | $23 |
| Shield Therapeutics Inc | 1 | $20 |
| Novartis | 1 | $19 |
| Convatec Inc. | 1 | $18 |
| Corcept Therapeutics | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Endo Pharmaceuticals Inc. | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PANORAMIC OPHTHALMOSCOPE$232
- SOLIQUA 100/33$225
- OCT OPHTHALMOSCOPE$116
- NFC-700$116
How this compares
$4,450 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 128 | $140,708 |
| OzempicSemaglutide | 56 | $81,461 |
| MounjaroTirzepatide | 50 | $71,872 |
| RybelsusSemaglutide | 26 | $44,376 |
| FarxigaDapagliflozin Propanediol | 54 | $43,881 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $39,336 |
| XareltoRivaroxaban | 21 | $22,129 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $15,838 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 15 | $14,918 |
| JanuviaSitagliptin Phosphate | 11 | $13,481 |
| MyrbetriqMirabegron | 12 | $9,177 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $8,273 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $7,146 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $6,256 |
| Ezetimibe | 277 | $6,105 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Combivent Respimat | $374 | $147,855140 claims |
| Novo NordiskOzempic, Rybelsus | $510 | $125,83782 claims |
| Lilly USA, LLCMounjaro, Olanzapine | $185 | $73,02863 claims |
| AstraZenecaFarxiga, Symbicort | $590 | $50,13669 claims |
| GSKTrelegy Ellipta | $187 | $39,33634 claims |
| Johnson & JohnsonXarelto | $93 | $22,12921 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $408 | $14,91815 claims |
| Astellas Pharma US IncMyrbetriq | $118 | $9,17712 claims |
| PfizerPaxlovid | $36 | $1,42917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Austin
- Cynthia BrinsonAustin$13.9M
- Gregg LucksingerAustin$11.4M
- Faith HolmesAustin$7.5M
- Gretchen CrookAustin$4.4M
- Matthew BrimberryAustin$3.8M
- Nomita KimAustin$3.3M
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.